Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935987 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
A Phase 1 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
NCT00935987 is a Phase 1 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 166 participants.
The verdict
NCT00935987, a Phase 1 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
Study Summary
This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
Interventions
- DRUG CYT387
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935987
The ClinicalTrials.gov registry entry for NCT00935987 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CYT387 is the first listed.
NCT00935987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00935987 about?
NCT00935987 is a clinical study titled "Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)". This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
What is the current status of trial NCT00935987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2009-11. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00935987?
The interventions under investigation include: CYT387 (DRUG).
Who is sponsoring clinical trial NCT00935987?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.